title: Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events.
abstract: Duchenne muscular dystrophy (DMD) is a progressive, lethal, muscle wasting disease that affects 1 of 3500 boys born worldwide. The disease results from mutation of the dystrophin gene that encodes a cytoskeletal protein associated with the muscle cell membrane. Although gene therapy will likely provide the cure for DMD, it remains on the distant horizon, emphasizing the need for more rapid development of palliative treatments that build on improved understanding of the complex pathology of dystrophin deficiency. In this review, we have focused on therapeutic strategies that target downstream events in the pathologic progression of DMD. Much of this work has been developed initially using the dystrophin-deficient mdx mouse to explore basic features of the pathophysiology of dystrophin deficiency and to test potential therapeutic interventions to slow, reverse, or compensate for functional losses that occur in muscular dystrophy. In some cases, the initial findings in the mdx model have led to clinical treatments for DMD boys that have produced improvements in muscle function and quality of life. Many of these investigations have concerned interventions that can affect protein balance in muscle, by inhibiting specific proteases implicated in the DMD pathology, or by providing anabolic factors or depleting catabolic factors that can contribute to muscle wasting. Other investigations have exploited the use of anti-inflammatory agents that can reduce the contribution of leukocytes to promoting secondary damage to dystrophic muscle. A third general strategy is designed to increase the regenerative capacity of dystrophic muscle and thereby help retain functional muscle mass. Each of these general approaches to slowing the pathology of dystrophin deficiency has yielded encouragement and suggests that targeting downstream events in dystrophinopathy can yield worthwhile, functional improvements in DMD.
authors.affiliation: Department of Physiological Science, University of California, Los Angeles, CA 90095, USA. jtidball@physci.ucla.edu
authors.forename: James G
authors.initials: JG
authors.lastname: Tidball
authors.forename: Michelle
authors.initials: M
authors.lastname: Wehling-Henricks
mesh_terms: D000818:Animals; D002648:Child; D006801:Humans; D020388:Muscular Dystrophy, Duchenne / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D010166:Palliative Care / Q000379:methods*